Iterum Therapeutics (ITRM) FDA Announcement summary

Introduction and purpose

• FDA approved Orlynvah (oral sulopenem) as the first oral penem antibiotic in the U.S. for treating uncomplicated urinary tract infections (UTIs) in adult women with limited or no alternative oral antibacterial options.

• Orlynvah is only the second FDA-approved uUTI treatment in two decades and the first new oral treatment for uncomplicated UTIs in 25 years.

• The call included forward-looking statements about the product's market potential and strategic plans for commercialization or licensing.

Details of approval or decision

• Approval is for uncomplicated UTIs caused by E. coli, Klebsiella pneumoniae, or Proteus mirabilis.

• The product is not indicated for complicated UTIs or intra-abdominal infections.

• The label includes standard antibiotic stewardship language and is competitive with other oral antibiotics.

• Iterum received its first FDA product approval with Orlynvah.

Impact on industry and stakeholders

• Orlynvah addresses a significant unmet need for new oral antibiotics amid rising resistance rates and limited options.

• The product is positioned for elevated risk patients, such as older women, those with diabetes, recurrent infections, or immune-compromising comorbidities.

• Market size is substantial, with an estimated 40 million prescriptions annually, and two-thirds potentially benefiting from Orlynvah.

• Iterum plans to pursue strategic transactions to maximize value from Orlynvah.